Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    18235122 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Conditions: Gastrointestinal Stromal Tumors;   KIT +;   Resected Gastrointestinal Stromal Tumors;   Non-metastatic;   High Risk of Recurrence
Intervention: Drug: Imatinib maintenance
2 Recruiting Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy
Condition: Gastrointestinal Stromal Tumor
Intervention:
3 Active, not recruiting Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
Condition: GIST
Interventions: Drug: Pazopanib;   Other: Best supportive care

Indicates status has not been verified in more than two years